This week has proven that the kingdom of fungi remains one of the most dynamic frontiers of modern science and industry. From the sterile halls of clinical laboratories to the damp floors of California’s forests, mushrooms are making headlines for their power to heal, their potential to clothe us, and their ability to harm.
The Psilocybin Milestone
The biggest news in “Psychopharmacology” arrived this week as Compass Pathways released data from its long-awaited late-stage clinical trials. Their synthetic psilocybin compound, COMP360, has successfully met its primary goals in treating “Treatment-Resistant Depression” (TRD). This represents the largest study of its kind to date. Researchers noted that patients who had failed multiple traditional antidepressants showed “clinically significant” improvements that lasted for months. If these results hold under FDA review, we could see the first federally approved psilocybin-based medicine by 2027.+1
Rapid Relief: The DMT Discovery
While psilocybin targets long-term change, another molecule is making waves for its speed. New results from a Phase II trial on DMT—the active ingredient in Ayahuasca—showed that a single injection led to a dramatic reduction in depression scores within just 14 days. Unlike psilocybin “trips,” which can last six hours, DMT sessions are much shorter, potentially making them more practical for integration into standard clinical workflows.
A Deadly “Super-Bloom” in California
In a somber turn, public health officials in California have declared a state of emergency regarding wild foraging. Following an exceptionally wet winter, the state is experiencing a “super-bloom” of the Amanita phalloides, better known as the Death Cap. This week alone, reports confirmed 40 hospitalizations. The mushroom, which often mimics edible puffballs or paddy straw mushrooms, causes irreversible liver and kidney failure. Experts are urging foragers to stick to store-bought varieties until the season subsides.+1
Mushroom Couture Goes Mainstream
Finally, the world of sustainable fashion reached a turning point. MycoWorks, the leader in mycelium-based materials, has launched an e-commerce platform for its “Reishi” leather. Previously only available to luxury giants like Hermès, this high-performance, carbon-negative material is now being offered directly to independent designers and smaller fashion houses. This move signals that mycelium is no longer just a “concept” material—it is a viable, scalable alternative to animal leather.
Sources:
- Healthbeat & Reuters: Compass Pathways Phase 3 Results (Feb 26, 2026)
- The Guardian: DMT Phase II Clinical Trial Report (Feb 25, 2026)
- California Dept. of Public Health: Toxic Fungi Advisory (Feb 2026)
- MycoWorks Industry Press Release (Feb 20, 2026)